ATAI

ATAI (AtaiBeckley) is a clinical-stage psychedelics biotech, not a business you can value on fundamentals. The filing is explicit: it has "no products that are approved for commercial sale and (has) not generated any commercial product revenue," and warns it "may never be profitable." The $4.09M of FY2025 "revenue" is not product sales, which makes the headline 478x P/S meaningless — you are buying a pipeline, not a P&L. The $660M net loss (vs $149M in 2024) is dominated by non-cash items tied to the Beckley Psytech combination and redomiciliation to the US; the truer cash signal is operating cash flow of -$103M, i.e. roughly $100M burned per year.

The balance sheet is the one genuine positive and the reason this is "avoid" on risk rather than "sell" on distress. Equity is positive at $222M, there is no long-term debt, and liabilities/equity is a benign 0.32x. Current assets of $276M dwarf $23.5M of current liabilities, so near-term solvency isn't the issue. But cash itself is only $85.3M against a ~$103M annual burn, there is $135M of short-term borrowings due, and management states it has "financed operations predominantly through the sale of equity securities and debt financings" and will need more — on 365M shares already outstanding, that points to continued dilution.